Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25656374 | 0.84 | NPSR1 (0.37) | MAPTALDH1A1TP53HSD17B10 | |
| SCHEMBL25728203 | 0.84 | NPSR1 (0.37) | MAPTALDH1A1TP53HSD17B10 | |
| SCHEMBL952143 | 0.81 | ELANE (0.39) | ELANEMAPTALDH1A1TP53HSD17B10 | |
| SCHEMBL27546454 | 0.81 | ELANE (0.39) | ELANEMAPTALDH1A1TP53HSD17B10 | |
| SCHEMBL25728204 | 0.78 | OPRK1 (0.43) | MAPTALDH1A1TP53 | |
| SCHEMBL25656378 | 0.78 | OPRK1 (0.43) | MAPTALDH1A1TP53 | |
| SCHEMBL11876232 | 0.77 | TRIM24 (0.37) | ALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL25118202 | 0.76 | ELANE (0.49) | ELANEALDH1A1 | |
| SCHEMBL24929755 | 0.76 | ALDH1A1 (0.34) | MAPTALDH1A1 | |
| SCHEMBL25158973 | 0.75 | MRGPRX1 (0.43) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230122228-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-04-20 | — | — | US | disclosed |
| WO-2023009187-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230122228-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | ELANE 3860/4885MAPT 4226/4885ALDH1A1 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.